Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(7):723–33.
Google Scholar
von Pawel J, Bordoni R, Satouchi M, et al. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2019;107:124–32.
Google Scholar
Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl. 2016;387(10027):1540–50.
Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
PubMed
Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46.
PubMed
Google Scholar
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
PubMed
PubMed Central
Google Scholar
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
PubMed
PubMed Central
Google Scholar
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl. 2017;389(10066):255–65.
Google Scholar
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.
PubMed
Google Scholar
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.
PubMed
Google Scholar
Novello S, Kowalski DM, Luft A, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006.
PubMed
PubMed Central
Google Scholar
Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992–8.
PubMed
PubMed Central
Google Scholar
Dall’Olio FG, Marabelle A, Caramella C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19(2):75–90.
PubMed
Google Scholar
Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer. 2020;20(1):1185.
PubMed
PubMed Central
Google Scholar
Geier M, Descourt R, Corre R, et al. ABCT-IMMUNOBZH : évaluation de l’efficacité du nivolumab dans la vraie vie chez 259 patients porteurs d’un cancer bronchique non à petites cellules de stade avancé. Rev Mal Respir. 2018;35(5):585.
Google Scholar
Gainor JF, Rizvi H, Jimenez Aguilar E, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(3):404–11.
Google Scholar
Debieuvre D, Juergens RA, Asselain B, et al. Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada. Lung Cancer. 2021;157:40–7.
PubMed
Google Scholar
Song M, Zhang Q, Song C, et al. The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. J Cachexia Sarcopenia Muscle. 2022;13(5):2504–14.
PubMed
PubMed Central
Google Scholar
Galvano A, Peri M, Guarini AA, et al. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol. 2020;12:1758835920942378.
PubMed
PubMed Central
Google Scholar
Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351–7.
PubMed
PubMed Central
Google Scholar
Ren F, Zhao T, Liu B, et al. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). OncoTargets Ther. 2019;12:4235–44.
Google Scholar
Faget J, Peters S, Quantin X, et al. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer. 2021;9(7): e002242.
PubMed
PubMed Central
Google Scholar
Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer Amst Neth. 2017;106:1–7.
Google Scholar
Soyano AE, Dholaria B, Marin-Acevedo JA, et al. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018;6(1):129.
PubMed
PubMed Central
Google Scholar
Takada K, Takamori S, Matsubara T, et al. Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: a multicenter retrospective study. PLoS ONE. 2020;15(11): e0241580.
PubMed
PubMed Central
Google Scholar
Luo D, Liu Q, Yu W, et al. Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study. Int J Colorectal Dis. 2018;33(9):1241–9.
PubMed
Google Scholar
Yao Z-X, Tu J-H, Zhou B, et al. Risk factors and survival prediction of pancreatic cancer with lung metastases: a population-based study. Front Oncol. 2022;12: 952531.
PubMed
PubMed Central
Google Scholar
Wood SL, Pernemalm M, Crosbie PA, et al. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40(4):558–66.
PubMed
Google Scholar
Liu S, Zhou F, Liu Z, et al. Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. Transl Lung Cancer Res. 2020;9(4):1053–66.
PubMed
PubMed Central
Google Scholar
Shin J, Keam B, Kim M, et al. Prognostic impact of newly proposed M descriptors in TNM classification of non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(3):520–8.
Google Scholar
Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–20.
PubMed
PubMed Central
Google Scholar
Ma K, Guo Q, Li X. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study. BMC Pulm Med. 2023;23(1):175.
PubMed
PubMed Central
Google Scholar
Yoneda T, Sone T, Koba H, et al. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clin Lung Cancer. 2022;S1525–7304(22):00055–9.
Google Scholar
Zhu Y, Chang X, Zhou R, et al. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in non-small cell lung cancer. Lung Cancer. 2022;166:189–96.
PubMed
Google Scholar
Del Conte A, De Carlo E, Bertoli E, et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int J Mol Sci. 2022;23(12):6832.
PubMed
PubMed Central
Google Scholar
Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5(5):620–30.
Google Scholar
Debieuvre D, Oster J-P, Riou R, et al. The new face of non-small-cell lung cancer in men: results of two French prospective epidemiological studies conducted 10 years apart. Lung Cancer Amst Neth. 2016;91:1–6.
Google Scholar
Nie R-C, Duan J-L, Liang Y, et al. Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis. Immunotherapy. 2020;12(18):1313–24.
PubMed
Google Scholar
Li JJN, Karim K, Sung M, et al. Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. Lung Cancer Amst Neth. 2020;150:159–63.
Google Scholar
Corke LK, Li JJN, Leighl NB, et al. Tobacco use and response to immune checkpoint inhibitor therapy in non-small cell lung cancer. Curr Oncol Tor Ont. 2022;29(9):6260–76.
Google Scholar
Norum J, Nieder C. Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open. 2018;3(6):e000406.
PubMed
PubMed Central
Google Scholar
Cho WCS, Tan KT, Ma VWS, et al. Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer. Oncotarget. 2018;9(91):36344–57.
PubMed
PubMed Central
Google Scholar
Adachi Y, Tamiya A, Taniguchi Y, et al. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med. 2019;9(4):1383–91.
PubMed
PubMed Central
Google Scholar
Mok T, Nakagawa K, Park K, et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722. J Clin Oncol. 2024;42(11):1252–64.
Comments (0)